U.S. markets close in 2 hours 46 minutes

Iovance Biotherapeutics, Inc. (IOVA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
29.69-1.06 (-3.45%)
As of 1:13PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close30.75
Bid29.72 x 1300
Ask29.77 x 800
Day's Range29.14 - 31.21
52 Week Range24.67 - 54.21
Avg. Volume1,831,890
Market Cap4.364B
Beta (5Y Monthly)0.82
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Iovance Gives Clinical Data Update For Melanoma Drug

    Iovance Gives Clinical Data Update For Melanoma Drug

    Iovance Biotherapeutics shared clinical data update for Lifileucel used in advanced melanoma from its Cohort 2 in the C-144-01 study. In the study, Lifileucel indicated a 36.4% overall response rate including 4.5% complete responses and 31.8% partial responses with the median duration of response (DOR) not being reached at 28.1 months of median study follow-up. Iovance Biotherapeutics (IOVA) will present the data at the upcoming American Association for Cancer Research (AACR) 2021 Annual Meeting Iovance Biotherapeutics’ President and CEO, Maria Fardis, Ph.D. said, “We are very excited to report our latest Cohort 2 melanoma data in an oral presentation at AACR. The long term follow up data show that median duration of response was not reached at 28.1 months of median study follow up.” “Furthermore, overall response rate remained at 36.4 percent and we saw a continued deepening of response in 17 percent of the patients. The data continue to demonstrate durability and depth of our lifileucel TIL therapy response after a one-time treatment, in a difficult to treat patient population with advanced melanoma. We are honored that AACR has chosen our melanoma Cohort 2 data to be featured in a clinical trials plenary session,” Fardis added. (See Iovance Biotherapeutics stock analysis on TipRanks) Following the clinical update from IOVA, Oppenheimer analyst Mark Breidenbach reiterated a Buy with a price target of $57 on the stock. Breidenbach said, “In our view, the biggest surprise was continuing tumor shrinkage in several patients long after treatment, including a CR [complete response] that developed at 24 months.” “We believe these data underscore a key selling point of TIL [tumor infiltrating lymphocytes] therapy—the possibility of extremely long-lasting responses for patients, regardless of prior PD-1 checkpoint antibody exposure. In our recent fireside chat, Iovance’s CEO suggested post-treatment tumor inflammation can take years to subside, which may explain the continuing tumor shrinkage,” Breidenbach added. Overall, the rest of the Street is bullish on the stock with a Strong Buy consensus rating based on 4 Buys. The average analyst price target of $53.50 implies that IOVA shares have approximately 77.2% upside potential to current levels. Related News: Microsoft Set To Acquire Nuance For $16B – Report Sanofi Snaps Up Tidal Therapeutics For $160M Sorrento’s Subsidiary Scilex Gets FDA Nod For ZTlido Label Expansion More recent articles from Smarter Analyst: Xencor Presents Positive Data For XmAb Antibodies Program Against Cancer Wall Street Roundup: Bullish & Bearish Calls Of The Day Sorrento’s Subsidiary Scilex Gets FDA Nod For ZTlido Label Expansion McGrath RentCorp Snaps Up Facility Rental Company Kitchens To Go

  • This Big Leap in Cancer Treatment Could Change the Landscape
    Motley Fool

    This Big Leap in Cancer Treatment Could Change the Landscape

    Much has been made of chimeric antigen receptor T-cell therapy (CAR T-cell therapy) over the past four to five years. It can target solid organ cancers, including melanoma, cervical cancer, head and neck cancer, and lung cancer, and has not had any unexpected off tumor tissue effects to date.

  • Is IOVA Stock A Buy or Sell?
    Insider Monkey

    Is IOVA Stock A Buy or Sell?

    With the fourth-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the first quarter of 2021. One of these stocks was Iovance Biotherapeutics, Inc. (NASDAQ:IOVA). Is IOVA stock a […]